Mr. David Burke reports

SERNOVA RESCHEDULES ITS ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS TO JANUARY 10, 2025

Sernova Corp. will hold its annual general and special meeting of shareholders on Friday, Jan. 10, 2025, at 1 p.m. Eastern Time. Due to the recent postal strike in Canada, the meeting, which had originally been scheduled to be held on Jan. 7, 2025, at 1 p.m. Eastern Time, was postponed so that Sernova and its agents are able to complete the mailing of its meeting materials through Canada Post to meet regulatory requirements.

The record date of Nov. 12, 2024, has not changed. To be effective, the proxy must be duly completed and signed and then deposited with the corporation's registrar and transfer agent, TMX Trust Company, P.O. Box 72, Agincourt, Ont., M1S 0A1, or voted by telephone or through the Internet (on-line) as specified in the proxy, no later than 1 p.m. Eastern Time, on Jan. 8, 2025. The management information circular for the meeting is available on the company's website and on the company's SEDAR+ profile.

About Sernova Corp.

Sernova is a clinical-stage company developing regenerative medicine therapeutics combining its Cell Pouch with human donor cells or stem cells to create a biohybrid organ. A biohybrid organ refers to a medical device designed to be implanted into the human body, where it integrates with existing living tissue to replicate or enhance the function of a natural organ, essentially aiming to restore normal organ function by combining living cells with non-living materials to mimic the properties of the original organ and seamlessly interact with surrounding tissues. This innovative approach aims to deliver a potentially revolutionary treatment for patients with chronic diseases, initially focusing on Type 1 diabetes and thyroid disorders.

We seek Safe Harbor.